CLEVELAND, Oct. 29, 2015 /PRNewswire/ -- GenomOncology announced today that David Lasecki has joined the company as Chief Commercialization Officer. In this position, Mr. Lasecki will lead the company's growth strategy by working with key stakeholders in the healthcare industry to promote the widespread adoption of precision medicine.
Mr. Lasecki has more than 16 years of molecular diagnostic and specialty pharmaceutical experience with a track record of enhancing product adoption resulting in improved market share and increased revenue throughout the United States. He most recently served as president of CompanionDx Labs with a specific focus on developing and overseeing its national sales and marketing strategies for the company's pharmacogenomics test offerings as well as supporting its reimbursement and payor strategy. In addition, he presided over the commercialization of CompanionDx's oncology-specific DNA sequencing and pharmacogenomics tests. Mr. Lasecki has also held a variety of sales and new business development roles with AmerisourceBergen's specialty group International Oncology Network, ION. During his tenure at ION, he worked closely with leading community oncology practices and branded and generic pharmaceutical manufacturers. David holds a BA from the University of Mount Union.
Through the creation of this new executive position, GenomOncology seeks to advance its position as a leader in oncology solutions for precision medicine. "With numerous molecular pathology labs now running on the company's platform, GenomOncology plans to accelerate its growth by working closely with both laboratories and clinicians to stimulate the adoption of medically beneficial precision medicine," said Manuel J. Glynias, President and CEO of GenomOncology. "David Lasecki, with his history of success and understanding of the needs of labs and practicing oncologists, is the perfect person to lead this strategic initiative."
GenomOncology is a healthcare technology company enabling precision medicine by transforming genomic data into actionable information. The GO Precision Medicine Portfolio™ is trusted by molecular pathologists and medical geneticists for streamlined development and production of knowledge- and guideline-driven cancer and hereditary disease tests. GenomOncology's technology allows multiple modes of genetic analysis to fuel integrated clinical decision support and research built on accumulating experience. Learn more at www.genomoncology.com.
For more information regarding this announcement, please contact:
Ben Salisbury, VP of New Products and Marketing
Email: [email protected]